Naperville, IL -- (ReleaseWire) -- 03/14/2014 -- Reportstack, provider of premium market research reports announces the addition of Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies 2014 market report to its offering
The present Competitive Intelligence Report about Biosimilar and Biosuperior Therapeutic Antibodies 2014 provides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies in the market, in the pipeline as next generation products and as biosimilar versions as of March 2014.
Marketed antibodies are attractive for companies to create next generation variants and biosimilar copies because they represent clinically and commercially validated products. New technologies such as Fc engineering, polyclonal mixtures, antibody drug conjugates or bispecific molecules as well as the expiration of patents stimulate the discovery and development of biosimilar and biosuperior/biobetter molecules.
Total sales of recombinant therapeutic monoclonal antibodies originating from companies located in regulated markets reached US$ 75.7 bln in the year 2013. Cumulated 2013 sales of branded therapeutic antibodies approaching patent expiry and, therefore, target of biosimilar substitution, reached US$ 58.6 bln.
The report lists specifically for each target the branded products with their 2013 sales and up-side indications in development, as well as follower, biosuperior and biosimilar antibody drug candidates in development.
2013 Sales data are provided for
The report includes a compilation of currently active projects in research and development of biosimilar and biosuperior antibodies against commercially and clinically validated targets:
Competitor projects are listed in a tabular format providing information on:
Target / Mechanism of Action,
Class of Compound,
R&D Stage and
additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
To view the table of contents for this market research report please visit